Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio para investigar la eficacia y seguridad de Sonrotoclax más zanubrutinib en comparación con placebo más zanubrutinib en adultos con linfoma de células del manto en recaída o refractario

27 de octubre de 2026 actualizado por: BeOne Medicines

Un estudio multicéntrico, doble ciego, aleatorizado de fase 3 de Sonrotoclax más zanubrutinib versus placebo más zanubrutinib en pacientes con linfoma de células del manto en recaída o refractario

The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.

Descripción general del estudio

Descripción detallada

Mantle cell lymphoma (MCL) is a rare, aggressive type of B-cell lymphoma. B-cells are white blood cells that help fight infections. Lymphoma is a cancer in the lymphatic system. Sometimes this type of cancer can come back after treatment (relapse), or it does not respond to treatment or stops responding to treatment (refractory).

Sonrotoclax is a drug which blocks a protein called B-cell lymphoma-2 (Bcl-2). Zanubrutinib works by blocking a protein called Bruton tyrosine kinase (BTK). Bcl-2 and BTK help certain blood cancer cells live and grow. By blocking Bcl-2 and BTK, sonrotoclax and zanubrutinib may slow or stop cancer cell growth and help them die.

The purpose of this study is to test if sonrotoclax plus zanubrutinib is safe and if it works better in adults with R/R MCL compared to zanubrutinib plus placebo. The main goal is to compare how long participants live without their disease getting worse. The study will also evaluate side effects and overall safety.

This study has two treatment groups. Participants will be randomly assigned (by chance) to receive sonrotoclax plus zanubrutinib or zanubrutinib plus placebo. All study treatments will be taken by mouth. Placebo is a pill that looks like the study drug but has no active ingredient. Participants and the study doctor will not know what treatment group the participant is assigned to during the study, unless there is an urgent medical need.

The study will enroll approximately 300 adults with R/R MCL at multiple centers worldwide.

The overall time to participate in this study is up to approximately 7 years. Participants will make regular visits to the clinic for treatment, health checks, blood tests, and tumor imaging tests.

Note: Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

300

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Chemnitz, Alemania, 09116
        • Reclutamiento
        • Klinikum Chemnitz Ggmbh
      • Frankfurt am Main, Alemania, 60596
        • Reclutamiento
        • Universitatsklinikum Frankfurt
      • Halle, Alemania, 06120
        • Reclutamiento
        • Universitatsklinikum Halle
      • Mutlangen, Alemania, 73557
        • Reclutamiento
        • Stauferklinikum Schwabisch Gmund Kliniken Ostalb
      • München, Alemania, 81377
        • Reclutamiento
        • Dept of Medicine Iii, University Hospitallmu
      • Siegen, Alemania, 57074
        • Reclutamiento
        • Diakonie Klinikum Jung Stilling Krankenhaus
      • Stuttgart, Alemania, 70376
        • Reclutamiento
        • Robert Bosch Krankenhaus, Abteilung Hamatologie, Onkologie Und Palliativmedizin
      • Caba, Argentina, CP1114
        • Activo, no reclutando
        • FUNDALEU
      • Caba, Argentina, 1425
        • Reclutamiento
        • Hospital Aleman
      • Ciudad Autonoma Buenos Aires, Argentina, 1413
        • Activo, no reclutando
        • Hospital Italiano de Buenos Aires
      • Córdoba, Argentina, X5000HUA
        • Activo, no reclutando
        • Hospital Universitario de Cordoba
    • Queensland
      • Birtinya, Queensland, Australia, QLD 4575
        • Activo, no reclutando
        • Sunshine Coast Hospital and Health Service
    • Victoria
      • Box Hill, Victoria, Australia, VIC 3128
        • Activo, no reclutando
        • Box Hill Hospital
      • Clayton, Victoria, Australia, VIC 3168
        • Activo, no reclutando
        • Monash Health
    • Western Australia
      • Cooloongup, Western Australia, Australia, WA 6168
        • Activo, no reclutando
        • Rockingham Hospital
      • West Perth, Western Australia, Australia, WA 6005
        • Activo, no reclutando
        • Perth Blood Institute
      • Sankt Pölten, Austria, 3100
        • Activo, no reclutando
        • Uk St Poelten
      • Barretos, Brasil, 14.784-400
        • Activo, no reclutando
        • Fundacao Pio Xii Hospital de Amor de Barretos
      • Belo Horizonte, Brasil, 30110-068
        • Activo, no reclutando
        • Hospital Felicio Rocho
      • Campinas, Brasil, 13083-878
        • Activo, no reclutando
        • Universidade de Campinas Centro de Hematologia E Hemoterapia
      • Caxias do Sul, Brasil, 95070-560
        • Activo, no reclutando
        • Fundacao Universidade de Caxias Do Sul
      • Curitiba, Brasil, 81520-060
        • Activo, no reclutando
        • Hospital Erasto Gaertner
      • Joinville, Brasil, 89201-260
        • Activo, no reclutando
        • Instituto Joinvilense de Hematologia E Oncologia
      • Porto AlegreRS, Brasil, 900350-903
        • Activo, no reclutando
        • Hospital de Clinicas de Porto Alegre
      • Recife, Brasil, 50040-000
        • Activo, no reclutando
        • Hospital Do Cancer de Pernambuco
      • São Paulo, Brasil, 05403-010
        • Activo, no reclutando
        • Hcfmusp Pesquisa Clinica Do Servico de Hematologia E Terapia Celular
      • Vitória, Brasil, 29043-260
        • Reclutamiento
        • Hospital Santa Rita de Cassia Afecc
    • Busan Gwang'Yeogsi
      • Seogu, Busan Gwang'Yeogsi, Corea del Sur, 49241
        • Activo, no reclutando
        • Pusan National University Hospital
    • Seoul Teugbyeolsi
      • GangnamGu, Seoul Teugbyeolsi, Corea del Sur, 06351
        • Activo, no reclutando
        • Samsung Medical Center
      • SeochoGu, Seoul Teugbyeolsi, Corea del Sur, 06591
        • Activo, no reclutando
        • The Catholic University of Korea, Seoul St Marys Hospital
      • Seoul, Seoul Teugbyeolsi, Corea del Sur, 03080
        • Activo, no reclutando
        • Seoul National University Hospital
      • SongpaGu, Seoul Teugbyeolsi, Corea del Sur, 05505
        • Activo, no reclutando
        • Asan Medical Center
      • Yeongdeungpo-gu, Seoul Teugbyeolsi, Corea del Sur, 07345
        • Activo, no reclutando
        • The Catholic University of Korea, Yeouido St Marys Hospital
      • Barcelona, España, 08036
        • Activo, no reclutando
        • Hospital Clinic de Barcelona
      • Barcelona, España, 08907
        • Activo, no reclutando
        • Ico H Duran I Reynals
      • Madrid, España, 28040
        • Terminado
        • Hospital Universitario Fundacion Jimenez Diaz
      • Majadahonda, España, 28222
        • Activo, no reclutando
        • H Puerta de Hierro Majadahonda
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35294-0004
        • Reclutamiento
        • University of Alabama At Birmingham Hospital
    • Arizona
      • Tucson, Arizona, Estados Unidos, 85724-0001
        • Reclutamiento
        • University of Arizona Cancer Center
    • California
      • Fresno, California, Estados Unidos, 93701
        • Reclutamiento
        • Ucsf Fresno
      • Irvine, California, Estados Unidos, 92618-3734
        • Reclutamiento
        • Kaiser Permanente Southern California
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06520-8028
        • Reclutamiento
        • Yale University Yale Cancer Center
    • Florida
      • Pembroke Pines, Florida, Estados Unidos, 33026-4119
        • Reclutamiento
        • Memorial Cancer Institute, Memorial Healthcare System
      • Weston, Florida, Estados Unidos, 33331-3609
        • Reclutamiento
        • Cleveland Clinic Florida
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60607
        • Reclutamiento
        • Rush University Medical Center
      • Chicago, Illinois, Estados Unidos, 60637-1443
        • Reclutamiento
        • University of Chicago Medical Center
    • Indiana
      • Fort Wayne, Indiana, Estados Unidos, 46804
        • Reclutamiento
        • Fort Wayne Medical Oncology and Hematology
    • Iowa
      • Waukee, Iowa, Estados Unidos, 50263
        • Reclutamiento
        • Mission Cancer and Blood
    • Louisiana
      • Baton Rouge, Louisiana, Estados Unidos, 70808-4365
        • Reclutamiento
        • Our Lady of the Lake Hospital
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21201
        • Reclutamiento
        • The University of Maryland Greenebaum Comprehensive Cancer Center
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215-5418
        • Reclutamiento
        • Dana Farber Cancer Institute Longwood Medical Center
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109-1382
        • Reclutamiento
        • University of Michigan
      • Grand Rapids, Michigan, Estados Unidos, 49503-2563
        • Reclutamiento
        • The Cancer and Hematology Centers
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905-0001
        • Reclutamiento
        • Mayo Clinic Rochester
    • Mississippi
      • Hattiesburg, Mississippi, Estados Unidos, 39401-7233
        • Reclutamiento
        • Hattiesburg Hematology and Oncology Clinic
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110-1010
        • Reclutamiento
        • Washington University School of Medicine
    • Nebraska
      • Grand Island, Nebraska, Estados Unidos, 68803
        • Reclutamiento
        • Nebraska Cancer Specialists St Francis Grand Island
      • Omaha, Nebraska, Estados Unidos, 68130-2042
        • Reclutamiento
        • Nebraska Cancer Specialists
    • New Jersey
      • Paramus, New Jersey, Estados Unidos, 07652
        • Reclutamiento
        • The Valley Hospital, Inc
    • New York
      • New York, New York, Estados Unidos, 10065-6800
        • Reclutamiento
        • Memorial Sloan Kettering Cancer Center Mskcc
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28204-2990
        • Reclutamiento
        • Atrium Health Levine Cancer Institute (Lci)
      • Durham, North Carolina, Estados Unidos, 27710
        • Reclutamiento
        • Duke University
      • Winston-Salem, North Carolina, Estados Unidos, 27157
        • Reclutamiento
        • Atrium Health Wake Forest Baptist
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44195-0001
        • Reclutamiento
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, Estados Unidos, 44106-1716
        • Reclutamiento
        • University Hospitals
      • Columbus, Ohio, Estados Unidos, 43210-1280
        • Reclutamiento
        • Ohio State University Comprehensive Cancer Center
      • Columbus, Ohio, Estados Unidos, 43214-3907
        • Reclutamiento
        • Ohio Health Research Institute
    • Pennsylvania
      • Hershey, Pennsylvania, Estados Unidos, 17033
        • Reclutamiento
        • Penn State Milton S Hershey Medical Center
      • West Reading, Pennsylvania, Estados Unidos, 19611-2143
        • Reclutamiento
        • McGlinn Cancer Institute
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37205
        • Reclutamiento
        • Tennessee Oncology
      • Nashville, Tennessee, Estados Unidos, 37205
        • Reclutamiento
        • Tennessee Oncology Nashville St Thomas Midtown Clinic
    • Texas
      • Houston, Texas, Estados Unidos, 77030-3907
        • Reclutamiento
        • Md Anderson Cancer Center
      • Round Rock, Texas, Estados Unidos, 78681-4019
        • Reclutamiento
        • Texas Oncology Austin Midtown
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22908-0817
        • Reclutamiento
        • University of Virginia
      • Gainesville, Virginia, Estados Unidos, 20155-3257
        • Reclutamiento
        • Virgina Cancer Specialists
      • Richmond, Virginia, Estados Unidos, 23298-5026
        • Reclutamiento
        • Vcu Massey Cancer Center
    • Washington
      • Vancouver, Washington, Estados Unidos, 98684-6930
        • Reclutamiento
        • Northwest Cancer Specialist, Pc(Us Oncology Research)
    • Wisconsin
      • Madison, Wisconsin, Estados Unidos, 53792-0001
        • Reclutamiento
        • University of Wisconsin
      • Montpellier, Francia, 34090
        • Reclutamiento
        • Chu Montpellier Hopital Saint Eloi
      • Nantes, Francia, 44000
        • Activo, no reclutando
        • Centre Hospitalier Universitaire Nantes Hotel Dieu
      • PierreBenite, Francia, 69495
        • Activo, no reclutando
        • Chu Hopital Lyon Sud
      • Tours, Francia, 37000
        • Reclutamiento
        • Chu Tours Hopital Bretonneau
      • Bologna, Italia, 40138
        • Activo, no reclutando
        • Policlinico Sorsola Malpighi, Aou Di Bologna
      • Lecce, Italia, 73100
        • Activo, no reclutando
        • Ospedale Vito Fazzi, Asl Lecce
      • Meldola, Italia, 47014
        • Activo, no reclutando
        • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst
      • Trieste, Italia, 34129
        • Activo, no reclutando
        • Azienda Sanitaria Universitaria Giuliano Isontina
      • Verona, Italia, 37134
        • Activo, no reclutando
        • Centroricerche Cliniche Di Verona Srl
      • Yokohama, Japón, 221-0855
        • Reclutamiento
        • Yokohama Municipal Citizens Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Japón, 464-8681
        • Reclutamiento
        • Aichi Cancer Center Hospital Clinical Oncology
      • Toyohashishi, Aichi-ken, Japón, 441-8570
        • Reclutamiento
        • Toyohashi Municipal Hospital
    • Chiba
      • Chiba, Chiba, Japón, 260-8717
        • Reclutamiento
        • Chiba Cancer Center
    • Ehime
      • Matsuyama, Ehime, Japón, 790 8524
        • Reclutamiento
        • Matsuyama Red Cross Hospital
    • Gifu
      • Ōgaki, Gifu, Japón, 503-8502
        • Reclutamiento
        • Ogaki Municipal Hospital
    • Hiroshima
      • Hiroshima, Hiroshima, Japón, 730-8619
        • Reclutamiento
        • Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
    • Hokkaido
      • Sapporo, Hokkaido, Japón, 060-8648
        • Reclutamiento
        • Hokkaido University Hospital
    • Hyōgo
      • KobeShi, Hyōgo, Japón, 650-0047
        • Reclutamiento
        • Kobe City Medical Center General Hospital
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Japón, 890-8520
        • Reclutamiento
        • Kagoshima University Hospital
    • Kanagawa
      • Yokohama, Kanagawa, Japón, 241-8515
        • Reclutamiento
        • Kanagawa Cancer Center
    • Miyagi
      • Sendai, Miyagi, Japón, 980-8574
        • Reclutamiento
        • Tohoku University Hospital
    • Okayama-ken
      • Kurashikishi, Okayama-ken, Japón, 710-8602
        • Reclutamiento
        • Kurashiki Central Hospital
      • Okayama, Okayama-ken, Japón, 701-1192
        • Reclutamiento
        • National Hospital Organization Okayama Medical Center
    • Osaka
      • Osaka, Osaka, Japón, 545-8586
        • Reclutamiento
        • Osaka Metropolitan University Hospital
      • Osakashi, Osaka, Japón, 543-8555
        • Reclutamiento
        • Osaka Red Cross Hospital
    • Saitama
      • Koshigaya, Saitama, Japón, 503-8502
        • Reclutamiento
        • Dokkyo Medical University Saitama Medical Center
    • Tokyo
      • Bunkyoku, Tokyo, Japón, 113-8519
        • Reclutamiento
        • Institute of Science Tokyo Hospital
      • Auckland, Nueva Zelanda, 0622
        • Activo, no reclutando
        • North Shore Hospital
      • Christchurch, Nueva Zelanda, 8011
        • Activo, no reclutando
        • Christchurch Hospital
      • Dunedin, Nueva Zelanda, 9016
        • Activo, no reclutando
        • Dunedin Hospital
      • Tauranga, Nueva Zelanda, 3112
        • Activo, no reclutando
        • Tauranga Hospital
      • Wellington, Nueva Zelanda, 6021
        • Activo, no reclutando
        • Wellington Regional Hospital (Ccdhb)
      • Krakow, Polonia, 30-727
        • Activo, no reclutando
        • Pratia McM Krakow
      • Lodz, Polonia, 93-510
        • Activo, no reclutando
        • Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
      • Lublin, Polonia, 20-090
        • Activo, no reclutando
        • Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
      • Skorzewo, Polonia, 60-185
        • Activo, no reclutando
        • Aidport Sp Z O O
      • Wroclaw, Polonia, 53-439
        • Activo, no reclutando
        • Dolnoslaskie Centrum Onkologii, Pulmonologii I Hematologii
    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100142
        • Reclutamiento
        • Beijing Cancer Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Porcelana, 630014
        • Reclutamiento
        • The First Affiliated Hospital of Chongqing Medical University
    • Guangdong
      • Guangzhou, Guangdong, Porcelana, 510515
        • Reclutamiento
        • Nanfang Hospital, Southern Medical University
      • Guangzhou, Guangdong, Porcelana, 510060
        • Reclutamiento
        • Sun Yat Sen University Cancer Center
    • Heilongjiang
      • Harbin, Heilongjiang, Porcelana, 150000
        • Reclutamiento
        • Harbin Medical University Cancer Hospital
    • Henan
      • Zhengzhou, Henan, Porcelana, 450052
        • Reclutamiento
        • The First Affiliated Hospital of Zhengzhou University
    • Hubei
      • Wuhan, Hubei, Porcelana, 430030
        • Activo, no reclutando
        • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
      • Wuhan, Hubei, Porcelana, 430022
        • Activo, no reclutando
        • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    • Jiangsu
      • Nanjing, Jiangsu, Porcelana, 210029
        • Reclutamiento
        • Jiangsu Province Hospital
      • Xuzhou, Jiangsu, Porcelana, 221000
        • Reclutamiento
        • The Affiliated Hospital of Xuzhou Medical University
    • Jiangxi
      • Nanchang, Jiangxi, Porcelana, 330029
        • Reclutamiento
        • Jiangxi Cancer Hospital
    • Liaoning
      • Shenyang, Liaoning, Porcelana, 110042
        • Reclutamiento
        • Liaoning Cancer Hospital and Institute
    • Shaanxi
      • Xi'an, Shaanxi, Porcelana, 710068
        • Reclutamiento
        • Shaanxi Provincial Peoples Hospital
    • Shandong
      • Linyi, Shandong, Porcelana, 276001
        • Reclutamiento
        • Linyi Cancer Hospital
      • Qingdao, Shandong, Porcelana, 266555
        • Reclutamiento
        • The Affiliated Hospital of Qingdao University Branch West Coast
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Porcelana, 200000
        • Reclutamiento
        • Fudan University Shanghai Cancer Center
    • Sichuan
      • Chengdu, Sichuan, Porcelana, 610071
        • Reclutamiento
        • Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, Porcelana, 310002
        • Reclutamiento
        • The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan
      • Wenzhou, Zhejiang, Porcelana, 325000
        • Reclutamiento
        • The First Affiliated Hospital of Wenzhou Medical University
      • San Juan, Puerto Rico, 00917
        • Reclutamiento
        • Auxilio Mutuo Cancer Center
      • Birmingham, Reino Unido, B9 5SS
        • Reclutamiento
        • Birmingham Heartlands Hospital
      • Bournemouth, Reino Unido, BH7 7DW
        • Reclutamiento
        • The Royal Bournemouth and Christchurch Hospitals Nhs Foundation
      • Glasgow, Reino Unido, G12 0YN
        • Reclutamiento
        • Beatson West of Scotland Cancer Centre
      • Headington, Reino Unido, OX3 7LE
        • Reclutamiento
        • Oxford University Hospitals Nhs Trust Churchill Hospital
      • London, Reino Unido, NW1 2PG
        • Reclutamiento
        • University College Hospital
      • Metropolitan Borough of Wirral, Reino Unido, CH63 4JY
        • Reclutamiento
        • Clatterbridge Cancer Centre
      • Plymouth, Reino Unido, PL6 8DH
        • Reclutamiento
        • Derriford Hospital
      • Ankara, Turquía (Türkiye), 06170
        • Activo, no reclutando
        • Etlik City Hospital
      • Dokuma, Turquía (Türkiye), 07025
        • Activo, no reclutando
        • Antalya Memorial Hospital
      • Kocaeli, Turquía (Türkiye), 41380
        • Activo, no reclutando
        • Kocaeli Universitesi Tip Fakultesi

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Histologically locally confirmed diagnosis of MCL based on the World Health Organization 2022 classification of Haematolymphoid Tumors (WHO-HAEM5), or based on International Consensus Classification (ICC)
  • Ability to provide archival or fresh tumor tissue for retrospective central confirmation of MCL diagnosis
  • Received 1 to 5 prior lines of systemic therapy including an anti-CD20 monoclonal antibody (mAb)-based immunotherapy or chemoimmunotherapy and requiring treatment in the opinion of the investigator
  • Relapsed or refractory disease after the last line of therapy
  • Measurable disease defined as ≥ 1 nodal lesion that is > 1.5 cm in longest diameter, or ≥ 1 extranodal lesion that is > 1 cm in longest diameter
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
  • Adequate organ function

Exclusion Criteria:

  • Prior therapy with B-cell lymphoma-2 inhibitor (BCL2i)
  • Prior therapy with BTK degraders
  • Prior therapy with covalent or non-covalent Bruton tyrosine kinase inhibitor (BTKi) unless the participant was intolerant of non-zanubrutinib covalent or non-covalent BTKi. Participants with refractory disease to BTKi therapy or relapse attributed to failure of BTKi therapy are ineligible.
  • Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug
  • Prior allogeneic stem cell transplant within 6 months of the first dose of the study drug
  • Known central nervous system involvement by lymphoma
  • Clinically significant cardiovascular disease
  • History of stroke or intracranial hemorrhage within 6 months before first dose of study drug

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Arm A: sonrotoclax plus zanubrutinib

Sonrotoclax and zanubrutinib will be administered in combination.

Administered orally

Otros nombres:
  • BGB-11417

Administered orally

Otros nombres:
  • Brukinsa
  • BGB-3111
Comparador de placebos: Arm B: placebo plus zanubrutinib

Placebo and zanubrutinib will be administered in combination.

Administered orally

Administered orally

Otros nombres:
  • Brukinsa
  • BGB-3111

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC)
Periodo de tiempo: Approximately 41 months

PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.

Approximately 41 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall Survival (OS)
Periodo de tiempo: Approximately 92 months

OS is defined as the time from randomization to the date of death from any cause.

Approximately 92 months
PFS as assessed by investigator (INV)
Periodo de tiempo: Approximately 58 months

PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.

Approximately 58 months
Overall Response Rate (ORR) as assessed by BIRC and by INV
Periodo de tiempo: Approximately 58 months

ORR is defined as the percentage of participants who achieved a best overall response of partial response (PR) or complete response (CR), per Lugano 2014 criteria.

Approximately 58 months
Duration of Response (DOR) as assessed by BIRC and by INV
Periodo de tiempo: Approximately 58 months

DOR is defined as the time from the first qualifying response to the date of progression or death, whichever occurs first.

Approximately 58 months
Complete Response Rate (CRR) as assessed by BIRC and by INV
Periodo de tiempo: Approximately 58 months

CRR is defined as the percentage of participants who achieved a best overall response of CR.

Approximately 58 months
Time to first response as assessed by BIRC and by INV
Periodo de tiempo: Approximately 58 months

Time to first response is defined as time from the date of randomization to first response.

Approximately 58 months
Time to initiation of new anticancer therapy
Periodo de tiempo: Approximately 58 months

Time to initiation of new anticancer therapy is defined as time from the date of randomization to the date of initiation of new anticancer therapy.

Approximately 58 months
Health-Related Quality of Life (HRQoL) as Assessed by the European Organisation of Research and Treatment of Cancer-Quality of Life Questionnaire Non-Hodgkin Lymphoma High Grade Module 29 (EORTC-QLQ-NHL-HG29)
Periodo de tiempo: Approximately 58 months

Patient-reported symptom burden, neuropathy, and physical condition/fatigue as measured by the EORTC-QLQ-NHL-HG29 questionnaire. The EORTC-QLQ-NHL-HG29 is the NHL-aggressive module of QLQ-C30; and it consists of 5 scales: Symptom burden due to disease and/or treatment (7 items), Neuropathy (2 items), Physical condition/Fatigue (5 items), Emotional impacts (4 items), and Worries/Fears health and functioning (11 items). Items are rated using a 4-point response scale ("not at all," "a little," "quite a bit," and "very much"). A higher score for all the multi-item scales and items represents a higher level of symptomatology or problems.

Approximately 58 months
Health-Related Quality of Life (HRQoL) as Assessed by the European Organisation of Research and Treatment of Cancer-Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
Periodo de tiempo: Approximately 58 months

Patient-reported global health status (GHS), role, and physical function as measured by the EORTC-QLQ-C30 questionnaire. The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best).

Approximately 58 months
Number of participants with treatment-emergent adverse events (TEAEs)
Periodo de tiempo: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 58 months

Number of participants with TEAEs, including laboratory values, vital signs, electrocardiogram results, and physical examination findings, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.

From the first dose of study drug(s) to 30 days after the last dose; up to approximately 58 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Study Director, BeOne Medicines

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de marzo de 2025

Finalización primaria (Estimado)

31 de agosto de 2028

Finalización del estudio (Estimado)

30 de marzo de 2032

Fechas de registro del estudio

Enviado por primera vez

16 de diciembre de 2024

Primero enviado que cumplió con los criterios de control de calidad

16 de diciembre de 2024

Publicado por primera vez (Actual)

19 de diciembre de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

27 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Marco de tiempo para compartir IPD

See plan description

Criterios de acceso compartido de IPD

See plan description

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir